Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
1.
J Pediatr ; 179: 226-232, 2016 12.
Article de Anglais | MEDLINE | ID: mdl-27622698

RÉSUMÉ

OBJECTIVE: To assess preventive care measure prescribing in children exposed to glucocorticoids and identify prescribing variation according to subspecialty and patient characteristics. STUDY DESIGN: Retrospective cohort study of children initiating chronic glucocorticoids in the gastroenterology, nephrology, and rheumatology divisions at a pediatric tertiary care center. Outcomes included 25-hydroxyvitamin D (25OHD) and lipid testing, pneumococcal polysaccharide (PPV) and influenza vaccination, and stress dose hydrocortisone prescriptions. RESULTS: A total of 701 children were followed for a median of 589 days. 25OHD testing was performed in 73%, lipid screening in 29%, and PPV and influenza vaccination in 16% and 78%, respectively. Hydrocortisone was prescribed in 2%. Across specialties, 25OHD, lipid screening, and PPV prescribing varied significantly (all P < .001). Using logistic regression adjusting for specialty, 25OHD testing was associated with older age, female sex, non-Hispanic ethnicity, and lower baseline height and body mass index z-scores (all P < .03). Lipid screening was associated with older age, higher baseline body mass index z-score, and lower baseline height z-score (all P < .01). Vaccinations were associated with lower age (P < .02), and PPV completion was associated with non-White race (P = .04). CONCLUSIONS: Among children chronically exposed to glucocorticoids, 25OHD testing and influenza vaccination were common, but lipid screening, pneumococcal vaccination, and stress dose hydrocortisone prescribing were infrequent. Except for influenza vaccination, preventive care measure use varied significantly across specialties. Quality improvement efforts are needed to optimize preventive care in this high-risk population.


Sujet(s)
Effets secondaires indésirables des médicaments/prévention et contrôle , Glucocorticoïdes/administration et posologie , Glucocorticoïdes/effets indésirables , Services de médecine préventive , Adolescent , Enfant , Enfant d'âge préscolaire , Études de cohortes , Femelle , Études de suivi , Humains , Nourrisson , Mâle , Études rétrospectives , Jeune adulte
2.
J Clin Rheumatol ; 21(8): 444-7, 2015 Dec.
Article de Anglais | MEDLINE | ID: mdl-26513308

RÉSUMÉ

We report a 6-year-old man with chronic severe recalcitrant bilateral anterior uveitis and a remote history of hemophagocytic lymphocytic histiocytosis secondary to Epstein-Barr virus infection. The patient was treated for idiopathic uveitis after an initial extensive evaluation failed to reveal a specific diagnosis. The patient failed to achieve sustained inactive disease with multiple monotherapies including topical glucocorticoid, methotrexate, infliximab, mycophenolate mofeti, and cyclosporine. Disease control was finally attained with a combination of cyclosporine and adalimumab. After more recent testing, he was found to have a novel deletion on the BIRC4 (baclovirus inhibitor of apoptosis repeat containing protein 4) gene, the causative gene for X-linked lymphoproliferative syndrome type 2. We conclude that male patients with chronic idiopathic uveitis should be questioned about a history of hemophagocytic lymphocytic histiocytosis during their workup and screened for BIRC4 mutation if appropriate.


Sujet(s)
Adalimumab/administration et posologie , Ciclosporine/administration et posologie , Infections à virus Epstein-Barr/complications , Maladies génétiques liées au chromosome X , Lymphohistiocytose hémophagocytaire , Syndromes lymphoprolifératifs , Uvéite , Protéine inhibitrice de l'apoptose liée au chromosome X/déficit , Antirhumatismaux/administration et posologie , Enfant , Maladies génétiques liées au chromosome X/diagnostic , Maladies génétiques liées au chromosome X/traitement médicamenteux , Maladies génétiques liées au chromosome X/génétique , Maladies génétiques liées au chromosome X/physiopathologie , Humains , Lymphohistiocytose hémophagocytaire/diagnostic , Lymphohistiocytose hémophagocytaire/étiologie , Syndromes lymphoprolifératifs/diagnostic , Syndromes lymphoprolifératifs/traitement médicamenteux , Syndromes lymphoprolifératifs/génétique , Syndromes lymphoprolifératifs/physiopathologie , Mâle , Mutation , Résultat thérapeutique , Uvéite/diagnostic , Uvéite/traitement médicamenteux , Uvéite/étiologie , Uvéite/physiopathologie , Protéine inhibitrice de l'apoptose liée au chromosome X/génétique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE